Venture Map · Round
Telum Therapeutics — Series A · €18M
Announced 2026-06-30 · Noáin · Healthtech & Bio
Endolysin-antimicrobials biotech secured an €18M Series A co-led by the AMR Action Fund and Inveready to take its lead candidate against drug-resistant hospital-acquired pneumonia into clinical development (press release June 30; most coverage July 1).
RoundSeries A
Amount€18M
LeadAMR Action Fund
Date2026-06-30
CityNoáin
SectorHealthtech & Bio
